Baxter Int'l Names Proposed Kidney Care Spinoff As Vantive
(RTTNews) - Medtech firm Baxter International Inc. (BAX) announced Tuesday that Vantive will be the name of the company's proposed spinoff of its Renal Care and Acute Therapies businesses.
Vantive is expected to launch as an independent, publicly traded company by July 2024 or earlier, subject to satisfaction of customary conditions. It will focus solely on therapies for kidney disease and other vital organ support.
The Vantive logo and full visual identity will be unveiled at a later date. Until completion of the proposed separation in 2024, the Kidney Care business will continue to operate as Baxter.
read more
Baxter International Boosts FY24 Outlook - Update
While reporting financial results for the second quarter on Tuesday, health care company Baxter International Inc. (BAX) raised its earnings, adjusted earnings and sales growth guidance for the full-year 2024. The company also provided outlook for the third quarter.
RTTNews
|
143 dni temu
Baxter Int'l Launches PERCLOT Absorbable Hemostatic Powder In The US
Baxter International Inc. (BAX) announced Monday the launch of PERCLOT Absorbable Hemostatic Powder in the U.S. PERCLOT is a passive, absorbable hemostatic powder that is ready to use and designed for patients with intact coagulation to address mild bleeding.
RTTNews
|
522 dni temu
Baxter International Q1 Results Top Estimates; Boosts FY23 Adj. EPS Outlook
Health care company Baxter International Inc. (BAX) reported Thursday that net income attributable to Baxter for the first quarter declined to $44 million or $0.09 per share from $71 million or $0.14 per share in the prior-year quarter. Excluding items, adjusted earnings for the quarter were $0.59 per share, compared to $0.93 per share in the year-ago quarter.
RTTNews
|
610 dni temu
Baxter Int'l Announces US Launch Of ZOSYN Premix
Medtech firm Baxter International Inc. (BAX) announced Tuesday the U.S. launch of ZOSYN (piperacillin and tazobactam) Injection. Zosyn premix is indicated for the treatment of multiple infections caused by susceptible bacteria and is available in Baxter's proprietary single-dose Galaxy containers.
RTTNews
|
633 dni temu
Baxter International Guides Q1, FY23 Adj. EPS Well Below Estimates; To Cut 5% Jobs - Update
While reporting financial results for the fourth quarter on Thursday, health care company Baxter International Inc. (BAX) initiated earnings, adjusted earnings and sales growth guidance for the first quarter and for the full-year 2023.
The company said the guidance for 2023 reflects a challenging first half of the year due to increased cost of sales resulting from elevated costs of inventory produced in the second half of 2022, reflecting the significant inflationary pressures the company experienced, that will impact earnings when the related inventory is sold in 2023. Baxter expects the impact from these inflationary pressures on its earnings to begin to ease in the second half of the year.
RTTNews
|
687 dni temu
Baxter International Again Slashes FY22 Outlook - Update
While reporting financial results for the second quarter on Thursday, health care company Baxter International Inc. (BAX) again lowered its earnings, adjusted earnings and sales growth for the full-year 2022. The company also provided outlook for the third quarter.
RTTNews
|
883 dni temu
U.S. Stocks Close Notably Lower; Nasdaq Sheds 1.5 Percent
U.S. stocks tumbled on Friday and the major averages all closed notably lower with the tech-laden Nasdaq suffering a more pronounced loss as yields on 10-Year Treasury Note rose to near 8-month high.
RTTNews
|
5g 43 minut temu
U.S. Stocks Down Firmly In Negative Territory; Nasdaq Tumbled 1.7 Percent
U.S. stocks are down firmly in negative territory Friday afternoon with rising Treasury yields contributing to the weakness. The major averages are all down in the red with the Nasdaq suffering a more pronounced loss.
RTTNews
|
7g 43 minut temu
